Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma | BeOne Medicines

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Beigene Study ID

BGB-3111-214

ClinicalTrials.gov ID

NCT03846427

EudraCT Number

2018-001284-24

China Drug Trials ID

CTR20180823

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan